The Federal Mifepristone Safety Review Is Still Unfinished While Senators Press Its Three Approved Manufacturers on Oversight
FDA says its mifepristone safety study remains under analysis, and a Senate committee report faults the drug's three sponsors for prescriber oversight.
Medical Daily ·